Skip to main content
DEINOVE logo

DEINOVE — Investor Relations & Filings

Ticker · ALDEI ISIN · FR0010879056 LEI · 969500BEJSRFER0F2K08 PA Professional, scientific and technical activities
Open in API
Filings indexed 300 across all filing types
Latest filing 2019-12-09 Capital/Financing Update
Country FR France
Listing PA ALDEI

About DEINOVE

https://www.deinove.com

DEINOVE is a biotechnology company that discovers, develops, and produces high-value compounds derived from rare bacteria and microorganisms, often referred to as 'microbial dark matter'. Leveraging a proprietary technology platform, the company harnesses the metabolic potential of extremophilic bacteria, such as Deinococcus, to create innovative solutions. Its primary applications are focused on developing novel bio-based active ingredients, including carotenoids, for the cosmetics sector, and discovering new antibiotics to address the global challenge of antimicrobial resistance.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Capital/Financing Update Classification · 1% confidence The document announces that DEINOVE and ESPCI Paris obtained a €300k grant from the ANR (French National Research Agency) for co-developing the Deinodrop technology related to antibiotic discovery. This is a specific announcement regarding funding and a research project, not a comprehensive financial report (like 10-K or IR), a management change (MANG), or a standard earnings release (ER). It details a specific financing/grant activity related to R&D. Among the provided codes, 'CAP' (Capital/Financing Update) is the most appropriate fit as it covers company fundraising and financing activities, even if the funding is a grant rather than debt or equity issuance. It is not a general regulatory filing (RNS) because it fits the specific 'CAP' definition better.
2019-12-09 English
Informations privilégiées / Autres communiqués
Capital/Financing Update Classification · 1% confidence The document is a press release dated December 9, 2019, announcing that DEINOVE and ESPCI Paris have obtained funding (€300k) from the ANR (Agence Nationale de la Recherche) for the co-development of the Deinodrop technology. This announcement details a specific partnership, funding acquisition, and project goals related to R&D, but it is not a full financial report (10-K, IR), an earnings release (ER), or a formal capital structure change (CAP). It is a specific announcement regarding research and development funding, which fits best under the general category of corporate news or a regulatory filing that doesn't fit elsewhere. Given the options, 'Capital/Financing Update' (CAP) is plausible because it involves receiving funding, but the core subject is R&D technology development. Since it is a formal announcement of a specific event (grant award) that is not a standard periodic report, 'Regulatory Filings' (RNS) serves as the most appropriate general category for non-standard corporate news announcements, although 'CAP' is a close second if the funding aspect is prioritized over the R&D nature. However, since it is a press release announcing a grant award, which is a form of corporate update, and not a formal filing like a 10-K or a specific financial statement, RNS is the safest fallback. Upon re-evaluation, receiving a grant is a significant financing/capital event for a biotech company, making CAP a strong candidate. Given the context of 'obtaining funding' (financement), CAP is more specific than the general RNS fallback. I will classify it as CAP.
2019-12-09 French
Inside Information / Other news releases
Board/Management Information Classification · 1% confidence The document explicitly announces significant changes in the company's leadership structure: the resignation of the CEO (Emmanuel PETIOT) and the appointment of an interim CEO (Dr. Charles WOLER), along with the appointment of the former CEO as a director. This content directly aligns with the definition of 'Board/Management Information' (MANG), which covers announcements of changes in the company's board of directors or senior management. The document is a formal announcement, not a full financial report or a transcript.
2019-12-06 English
Informations privilégiées / Autres communiqués
Board/Management Information Classification · 1% confidence The document explicitly announces significant changes in the company's senior management: the resignation of the CEO (Directeur Général), the appointment of the Chairman of the Board as interim CEO, and the co-option of the resigning CEO as a director to assist with partnerships. This content directly relates to changes in the board of directors or senior management personnel. Therefore, the appropriate classification is Board/Management Information (MANG). The document length (4779 chars) is substantial enough to be the primary announcement, not just a brief notice of publication.
2019-12-06 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release dated November 4, 2019, announcing the preview of a new cosmetic ingredient (a carotenoid) at the In-Cosmetics Asia 2019 exhibition, with a global launch scheduled for In-Cosmetics Global 2020. It details product features, market context (Asia cosmetics market), and includes quotes from management. This type of announcement, focusing on product development, market strategy, and upcoming industry events, is characteristic of general corporate news or investor relations material, but it is not a formal regulatory filing like a 10-K, an earnings release (ER), or a specific financial report (IR, AR). Since it is a general announcement about business activities and product pipeline updates, and it doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Dividend (DIV), it falls best under the general Regulatory Filings (RNS) category, which serves as a fallback for miscellaneous corporate announcements not covered elsewhere, or potentially Investor Presentation (IP) if it were a slide deck, but this reads like a press release. Given the options, RNS is the most appropriate catch-all for a non-standard press release detailing business updates.
2019-11-04 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated November 4, 2019, announcing that DEINOVE will present its second innovative carotenoid ingredient at the In-Cosmetics Asia trade show. It details the product's properties, market potential (especially in Asia), and future launch plans (In-cosmetics Global 2020). This type of announcement, focusing on product development, market strategy, and upcoming industry events, is characteristic of an Earnings Release (ER) if it were summarizing financial results, or more generally, a corporate announcement. Since it is not a formal regulatory filing like a 10-K, a quarterly report (IR), or a specific transaction notice (DIV, SHA, POS), and it serves to inform the market about a significant business development (new product presentation), it fits best under the general category of an Earnings Release (ER) which often includes business updates alongside or instead of pure financial figures, or potentially Regulatory Filings (RNS) as a general announcement. Given the content is a forward-looking business update and product promotion, and it is not a transcript (CT) or a formal presentation (IP), 'ER' is often used for these types of initial business updates, even if financial results are minimal or absent. However, since it is primarily an announcement about an upcoming presentation at a trade show, it functions as a general corporate news release. In the absence of explicit financial results, 'RNS' (Regulatory Filings - general/miscellaneous announcement) is a strong candidate. Comparing the options, 'ER' (Earnings Release) is often used for press releases announcing key business milestones or product news that precedes a formal earnings report. Given the context of a biotech company announcing a new ingredient presentation, this is a significant business update. I will classify it as an Earnings Release (ER) as it functions as a major business update announcement, though RNS is a close second if ER is strictly reserved for financial figures.
2019-11-04 French

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.